Bullish Charts and Commercial Breakthroughs For Florida Biomanufacturer Could Fuel Upwards Valuation
Source: Stewart Thomson  (7/14/26)
Technical Analyst Stewart Thomson takes a look at Dyadic International Inc. (DYAI:NASDAQ) as it secures strategic partnerships in the human and animal health, food technology, cell culture media, and industrial enzyme sectors. More >

Satellos Bioscience Delivers Promising DMD Data With Fast Track Win
Source: Streetwise Reports  (7/10/26)
Satellos Bioscience reports strong six-month TRAILHEAD data for SAT-3247 in DMD adults, secures Fast Track status, and advances pediatric trials amid growing muscle disease market opportunity. More >

Biotech With Muscle Disease Drug Uncovers Results in Trial Data
Source: Streetwise Reports  (7/9/26)
Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) shares promising data from its study evaluating a drug to fight Duchenne muscular dystrophy. Find out why at least one expert says the study "delivered" great data. More >

Digital Health Platform Lands Access to Hundreds of Thousands of Covered Lives
Source: Streetwise Reports  (7/8/26)
DarioHealth Corp. (DRIO:NASDAQ) signed a new agreement through its Amwell partnership that makes its cardiometabolic platform available to a major Arizona health insurer's ASO business, representing hundreds of thousands of covered lives. More >

NASDAQ-Listed Duchenne Muscular Dystrophy Drugmaker Wins FDA Filing Acceptance Despite Confirmatory Trial Miss
Source: Mitchell Kapoor  (7/8/26)
The FDA accepted the company's morpholino oligomer filings with a February 2027 PDUFA date, but a missed confirmatory trial endpoint clouds its path to full approval. More >

Air Force Bases Renew Their Contracts With Cleantech Pioneer
Source: Streetwise Reports  (7/7/26)
Cleantech and life sciences innovator BioLargo Inc. (BLGO:OTCQX) says its engineering division has secured contract renewals worth over US$1.4 million. Find out why experts like this technology incubator's structure. More >

First-of-Its-Kind US Brain Imaging Clinic Takes Delivery of Key PET Scanner
Source: Streetwise Reports  (7/7/26)
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) received its first brain-dedicated PET scanning system for its flagship Florida NovaScan Neuroimaging Clinic, which the company said will be the first U.S. facility dedicated to brain-only PET imaging for Alzheimer's disease and other neurological conditions. More >

Grey Matters Health Inc. Targets Alzheimer's PET Imaging Opportunity
Source: Streetwise Reports  (7/7/26)
Grey Matters Health Inc. advances first U.S. brain-dedicated PET clinic for Alzheimer's detection amid surging diagnostics demand. Learn the key facts for investors. More >

BioLargo (BLGO) Aligns CEO Pay With Growth as Contracts Renew
Source: Streetwise Reports  (7/7/26)
BioLargo Inc. (BLGO) secures $1.4M Air Force contract renewals while advancing PFAS and wound care technologies through key partnerships and aligned leadership incentives. More >

How Do Analysts Rate This Biotech Focused on Chronic Inflammatory Diseases?
Source: Streetwise Reports  (7/6/26)
Find out what analysts think of clinical-stage biotech Abivax SA (ABVX:NASDAQ), which is focusing on harnessing the immune response in patients with chronic inflammatory diseases. More >

Abivax SA (ABVX) UC Opportunity: Oral Therapy Catalyst
Source: Streetwise Reports  (7/6/26)
Abivax SA (ABVX) advances obefazimod through Phase 3 success in ulcerative colitis with NDA filing targeted for late 2026. Learn why this oral miR-124 therapy stands out for investors now. More >

French Clinical-Stage Biotech's UC Drug Faces 'Best in Disease' Doubts as Analyst Lifts Target Ahead of 4Q26 FDA Filing
Source: David Nierengarten  (7/6/26)
A Wedbush analyst raised its target on a French biopharma's ulcerative colitis candidate but disputed bullish efficacy claims, flagging Jak competition and a 2027 Crohn's readout. More >

Drug Developer Scores Major FDA Nod, Eyes Big Gains in Muscle Disease Market
Source: Streetwise Reports  (7/2/26)
Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) earns FDA Fast Track designation for its Duchenne treatment SAT-3247, positioning the company for potential breakthrough gains. More >

Abivax SA (ABVX:NASDAQ) UC Data Fuels Biotech Opportunity
Source: Streetwise Reports  (7/2/26)
Abivax SA (ABVX:NASDAQ) reports strong obefazimod maintenance results in ulcerative colitis. Explore sector growth, analyst targets, catalysts, and what it means for investors. More >

Satellos Bioscience Fast Track Win Fuels DMD Hopes
Source: Streetwise Reports  (7/2/26)
Satellos Bioscience earns FDA Fast Track for SAT-3247 in Duchenne. Explore the market opportunity, clinical catalysts, analyst targets, and what retail investors should know now. More >

Digital Health Pioneer Targets Massive Breakthrough Chronic Care Market
Source: Streetwise Reports  (7/1/26)
AI-driven digital health solutions pioneer DarioHealth Corp. (DRIO:NASDAQ) announces a partnership that it says will give it access to a network spanning all 50 states. Find out why analysts like the direction the company is taking. More >

DarioHealth (DRIO) Expands Reach via Beluga Health Deal
Source: Streetwise Reports  (7/1/26)
DarioHealth (DRIO) integrates its AI platform with Beluga Health's network to scale provider-backed care. Discover growth catalysts, analyst targets, and investor considerations. More >

Clinical-Stage Biotech Discloses Colitis Retreatment Results, Gets Mixed Ratings
Source: Streetwise Reports  (7/1/26)
Abivax SA (ABVX:NASDAQ) reports 69.7% clinical response and 45.0% remission rates in relapsed UC patients retreated with obefazimod in Phase 3 trial. More >

Viking Therapeutics Expands Obesity Pipeline With VK3019 Phase 1
Source: Streetwise Reports  (6/27/26)
Viking Therapeutics launches Phase 1 trial for VK3019 amylin agonist. Discover how this dual-receptor candidate fits the company's expanding obesity strategy and upcoming catalysts for investors. More >

uniQure Epilepsy Gene Therapy Data Draws Investor Focus
Source: Streetwise Reports  (6/26/26)
uniQure reports early AMT-260 results for refractory MTLE. See the trial data, pipeline catalysts, analyst price target, and what retail investors should watch next. More >

A New Obesity Drug Just Reached Human Trials. Here's What Comes Next
Source: Streetwise Reports  (6/26/26)
Viking Therapeutics Inc. (VKTX:NASDAQ) initiated a Phase 1 clinical trial of its investigational weight-loss candidate VK3019, following FDA clearance of its IND application. More >

Gene Therapy Co. Announces Initial Data for Refractory Epilepsy Treatment, Gets Buy Rating
Source: Streetwise Reports  (6/25/26)
uniQure N.V. (QURE:NASDAQ) announced initial six-month data for AMT-260 treating refractory epilepsy, with three of six patients showing 79-100% seizure reduction. More >

San Diego Biopharma Begins First-in-Human Dosing of Obesity Drug as Phase 3 Catalysts Approach
Source: Dr. Joseph Pantginis  (6/25/26)
A San Diego clinical-stage biopharma dosed its first patient in a Phase 1 obesity study while advancing late-stage weight-loss programs toward key 20262027 readouts. More >

Grey Matters Health Inc. Advances US Alzheimer's Clinics
Source: Streetwise Reports  (6/23/26)
Grey Matters Health Inc. closes CA$1.25M financing to launch brain-specific PET clinics targeting the expanding Alzheimer's diagnostics market and early detection demand. More >

DarioHealth: Chronic Care Platform Drives Value
Source: Streetwise Reports  (6/23/26)
DarioHealth targets the booming digital health market with a multi-condition platform backed by 27 ADA studies. See pipeline growth, analyst targets, and key catalysts for investors. More >